Skip to main content
SpringerLink
Log in

Targeted Therapy of the Epidermal Growth Factor Receptor in the Treatment of Pancreatic Cancer

  • Chapter
Book cover Pancreatic Cancer

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 177))

Abstract

The epidermal growth factor receptor (EGFR)- mediated pathway is one of the most promising targets for the development of new strategies in anticancer treatments. The so-called “small molecule” tyrosine kinase inhibitor erlotinib has gained marketing authorization in the United States for advanced adenocarcinoma of the lung and for pancreatic cancer, whereas the antibody cetuximab is registered for metastatic colorectal cancer and cancers of the head and neck. Ongoing studies are evaluating the impact of EGFR-targeting therapy in the treatment of locally advanced and metastatic pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 159.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 209.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 209.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alessi DR, Cohen P (1998) Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 8:55–62

    Article  PubMed  CAS  Google Scholar 

  2. Blaszkowsky LS, Kulke KH, Ryan DP, Clark JW, Meyerhardt J, Zhu AX, Lawrence C, Fuchs CS (2005) A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancer. Proc ASCO 2005. J Clin Oncol 23:4099

    Google Scholar 

  3. Bromberg J, Darnell JE Jr (2000) The role of STATs in transcriptional control and their impact on cellular function. Oncogene 1519:2468–2473

    Article  Google Scholar 

  4. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413

    PubMed  CAS  Google Scholar 

  5. Czito BG, Willett CG, Bendell JC, Morse MA, Tyler DS, Fernando NH, Mantyh CR, Blobe GC, Honeycutt W, Yu D, Clary BM, Pappas TN, Ludwig KA, Hurwitz HI (2006) Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol 124:656–662

    Article  Google Scholar 

  6. Durkin AJ, Osborne DA, Yeatman TJ, Rosemurgy AS, Armstrong C, Zervos EE (2006) EGF receptor antagonism improves survival in a murine model of pancreatic adenocarcinoma. J Surg Res 135:195–201

    Article  PubMed  CAS  Google Scholar 

  7. Earp HS, Dawson TL, Li X, Yu H (1995) Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat 35:115–132

    Article  PubMed  CAS  Google Scholar 

  8. Epelbaum R, Schnaider J, Gluzman A, Figer A (2007) Erlotinib as a single-agent therapy in patients with advanced pancreatic cancer. ASCO Gastrointest Cancers Symp, abstr 202

    Google Scholar 

  9. Funatomi H, Itakura J, Ishiwata T, Pastan I, Thompson SA, Johnson GR, Korc M (1997) Amphiregulin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor-targeted therapy. Int J Cancer 2972:512–517

    Article  Google Scholar 

  10. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY (1993) Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4:121–133

    PubMed  CAS  Google Scholar 

  11. Gomez-Martin C, Camara ‚J, Rubio B, Amador H, Cortes Funes H, Gravalos C, Hidalgo M (2007) A phase I study of erlotinib, bevacizumab, and gemcitabine in patients with advanced pancreatic cancer. ASCO Gastrointest Cancers Symp, abstr 199

    Google Scholar 

  12. Gschwind A, Zwick E, Prenzel N, Leserer M, Ullrich A (2001) Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene 20:1594–1600

    Article  PubMed  CAS  Google Scholar 

  13. Krempien RC, Münter MW, Timke C, Huber PE, Friess H, Heeger S, Herfarth KK, Abdollahi A, Hartung G, Buchler MW, Debus J (2006) Phase II study evaluating trimodal therapy with cetuximab intensity modulated radiotherapy (IMRT) and gemcitabine for patients with locally advanced pancreatic cancer (ISRCTN56652283). Proc ASCO Annual Meeting 2006. J Clin Oncol 24:4100

    Article  Google Scholar 

  14. Kullmann F, Hollerbach S, Dollinger MM, Harder J, Fuchs M, Messmann H, Trojan J, Gäbele E, Hinke A, Endlicher E (2007) Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in 1st line metastatic pancreatic cancer. First results from a multicenter phase II study. ASCO Gastrointest Cancers Symp, abstr 128

    Google Scholar 

  15. Lemoine NR, Hughes CM, Barton CM, Poulsom R, Jeffery RE, Kloppel G, Hall PA, Gullick WJ (1992) The epidermal growth factor receptor in human pancreatic cancer. J Pathol 166:7–12

    Article  PubMed  CAS  Google Scholar 

  16. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W (2006) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. JCO early release, published online ahead of print, 23 April 2007. J Clin Oncol 10.1200/JCO 07.9525

    Google Scholar 

  17. Ng SS, Tsao MS, Nicklee T, Hedley DW (2002) Effects of the epidermal growth factor receptor inhibitor OSI–774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther 1:777–783

    PubMed  CAS  Google Scholar 

  18. Pipas JM, Zaki B, Suriwinata AA, Tsapakos MJ, Ripple GH, Colacchio TA, Sutton JE, Gordon SR, Kasibhatla MS, Barth RJ (2006) Cetuximab, intensity-modulated radiotherapy (IMRT), and twice-weekly gemcitabine for pancreatic adenocarcinoma. Proc ASCO Annual Meeting. J Clin Oncol 24:14056

    Google Scholar 

  19. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A (2001) The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8:11–31

    Article  PubMed  CAS  Google Scholar 

  20. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232

    Article  PubMed  CAS  Google Scholar 

  21. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, et al. (2005) Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 14353:123–132

    Article  Google Scholar 

  22. Sonenshein GE (1997) Rel/NF-kappaB transcription factors and the control of apoptosis. Semin Cancer Biol 8:113–119

    Article  PubMed  CAS  Google Scholar 

  23. Tsai JY, Iannitti DA, Safran H (2003) Combined modality therapy for pancreatic cancer. Semin Oncol 30:71–79

    Article  PubMed  CAS  Google Scholar 

  24. Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61:203–212

    Article  PubMed  CAS  Google Scholar 

  25. Xiong HQ, Abbruzzese JL (2002) Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol 29:31–37

    PubMed  CAS  Google Scholar 

  26. Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, Needle M, Abbruzzese JL (2004) Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 122:2610–2616

    Article  Google Scholar 

  27. Xu YH, Richert N, Ito S, Merlino GT, Pastan I (1984) Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines. Proc Natl Acad Sci USA 81:7308–7312

    Article  PubMed  CAS  Google Scholar 

  28. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M (1993) Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 13:565–569

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Merck Pharma GmbH, Alsfelder Str. 17, 64289, Darmstadt, Germany

    Steffen Heeger

Authors
  1. Steffen Heeger
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Heeger, S. (2008). Targeted Therapy of the Epidermal Growth Factor Receptor in the Treatment of Pancreatic Cancer. In: Pancreatic Cancer. Recent Results in Cancer Research, vol 177. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-71279-4_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-71279-4_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-71266-4

  • Online ISBN: 978-3-540-71279-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation